Natera (NTRA) announced the completion of enrollment in ACES-EMB, the first randomized-controlled trial evaluating whether Natera’s Prospera Heart test can replace routine invasive biopsies for rejection monitoring in heart transplant recipients.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRA:
- Natera’s Prospera featured in interventional study advancing in lung transplant
- Natera announces publication of validation study for Latitude tissue-free assay
- Natera Targets Endometrial Cancer With New Signatera Trial, Expanding Its MRD Opportunity
- Natera’s SCORE Study Builds Real-World Evidence for Cancer MRD Testing
- Natera: Accelerating MRD Momentum, Revenue Outperformance, and Improving Cash Profile Support Buy Rating